Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Aushon BioSystems Appoints Industry Veteran Susan Vogt Chief Executive Officer

Published: Tuesday, April 16, 2013
Last Updated: Tuesday, April 16, 2013
Bookmark and Share
Former SeraCare CEO and Millipore executive to guide strategic direction of life sciences services and technology company.

Aushon BioSystems announced the appointment of Susan Vogt as chief executive officer. Vogt brings more than 30 years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics markets to her new role. Founder and former CEO Pete Honkanen will assume the role of chief operating officer and continue as a board director.

Vogt's experience includes leadership roles at both small and large private and public companies. Most recently, Vogt led the turnaround of diagnostics reagents company SeraCare Life Sciences as president and CEO, where she successfully re-listed the company on NASDAQ and returned the company to growth and profitability. Previously, Vogt held numerous senior level positions at Millipore Corporation, including corporate officer and president of the company’s biopharmaceutical division. She currently serves as non-executive director of TAP BioSystems, and has previously served on the board of directors and advisory boards of a number of other private and publicly-held companies. Vogt holds an MBA from Boston University and a BA from Brown University.

“With sound technology, an elegant, easy-to-use platform and a strong customer base, Aushon is well-positioned to lead the market as the demand for multiplexing in the life sciences continues to grow,” said Vogt. “Our technology enables research that’s critical to the development of both therapeutics and diagnostics, and I look forward to driving the company’s future growth.”

Aushon provides a suite of multiplex immunoassay products and services for the discovery and development of the biomarkers necessary to enable personalized medicine innovation. Multiplexing involves simultaneously measuring and comparing multiple proteins – an improvement over today’s standard which measures one at a time. Fueled by a growing market for multiplexing, Aushon recently announced an anticipated 30 percent year-over-year revenue growth in 2013 and added Thomas Mac Mahon, former president and CEO of Laboratory Corporation of America® Holdings (LabCorp®), to its board of directors.

“Susan is joining Aushon at an exciting time, as we’re expanding to meet increasing demand for our technologies and services by pharmaceutical, biotech and other life sciences research organizations,” said Honkanen. “Her appointment is further evidence of Aushon’s momentum in helping our customers drive the development of new tests and therapies, enabling personalized medicine and, ultimately, better healthcare for patients.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aushon Biosystems Thrives with Increasing Demand for Personalized Medicine
Adds former LabCorp leader Thomas Mac Mahon to board of directors, expects further growth in 2013.
Wednesday, February 27, 2013
Aushon BioSystems and Peking University Cancer Hospital to Collaborate
Aushon BioSystems, Inc. announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital (“PUCH”), Beijing, China. The primary goal for the collaboration is to develop predictive diagnostic markers for liver metastases of colorectal cancer.
Friday, February 11, 2011
Scientific News
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Potential New Diagnosis and Therapy for Breast Cancer
Scientists at the University of York, using clinical specimens from charity Breast Cancer Now’s Tissue Bank, have conducted new research into a specific sodium channel that indicates the presence of cancer cells and affects tumour growth rates.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos